




Join Keystone Symposia
for the 2016 conference on:

Tuberculosis Co-Morbidities and Immunopathogenesis

February 28–March 3, 2016

Keystone Resort | Keystone, Colorado | USA

Scientific Organizers:

Hardy Kornfeld, Sarah M. Fortune and Thomas R. Hawn

Tuberculosis remains one of the most significant infectious disease threats to global health despite the availability of effective antimicrobials for more than 50 years. The focus of this Keystone Symposia meeting is on co-morbidities that are major driving factors in the TB pandemic and that may cause informative perturbations of immunity. This symposium explores metabolic disorders, environmental exposures, co-infections, age and genetic variants that influence host-pathogen interactions in TB. Plenary sessions will combine rather than separate topics focused on the host and the pathogen, and perspectives from laboratory and field studies. Speakers are encouraged to challenge existing dogma and offer new paradigms as a basis for more effective approaches to TB prevention and treatment.

Session Topics:

- Metabolism and Co-Morbidity I & II
- Workshop 1: Non-Classical Immunity
- Genetic Variation: A Different Type of Co-Morbidity?
- HIV/TB Co-Morbidity
- Workshop 2: Microbiology
- Pediatrics: Is Immaturity a Co-Morbidity?
- Impact of Co-Infections on TB Pathogenesis
- Workshop 3: Tfh and GCs in Disease
- Host-Pathogen Interactions
- Workshop 3: Host-Directed Therapies
- Host-Directed Therapeutics:
Co-Opting Treatment of Co-Morbidities



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Oct 29, 2015

Abstract Deadline: Dec 1, 2015

Discounted Registration Deadline: Jan 5, 2016

For additional details, visit www.keystonesymposia.org/16B6.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology

Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Tuberculosis Co-Morbidities and Immunopathogenesis (B6)

February 28-March 3, 2016 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Hardy Kornfeld, Sarah M. Fortune and Thomas R. Hawn

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: September 29, 2015 / Abstract & Scholarship Deadline: October 29, 2015 / Abstract Deadline: December 1, 2015 / Discounted Registration Deadline: January 5, 2016

SUNDAY, FEBRUARY 28

Arrival and Registration

MONDAY, FEBRUARY 29

Metabolism and Co-Morbidity I

Gökhan S. Hotamisligil, Harvard University, USA
Lipid Metabolism and ER Stress

Larry S. Schlesinger, Ohio State University, USA
Metabolism and Inflammation: A Monocytic Convergence

Kyu Y. Rhee, Weill Cornell Medical College, USA
Bacterial Metabolism in a Changing Host Environment

Sarah A. Stanley, University of California, Berkeley, USA
Macrophage Metabolism and Antimicrobial Effectors

Short Talk(s) Chosen from Abstracts

Workshop 1: Non-Classical Immunity

Short Talks Chosen from Abstracts

Genetic Variation: A Different Type of Co-Morbidity?

Thomas R. Hawn, University of Washington, USA
Innate Resistance to Mtb Infection

Igor B. Kramnik, Boston University, USA
Control of Lung Damage and Carcinogenesis in TB: Genes Meet the Environment

Sarah M. Fortune, Harvard School of Public Health, USA
Talk Title to be Announced

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 1

HIV/TB Co-Morbidity

Robert J. Wilkinson, University of Cape Town, South Africa
Understanding and Intervening in HIV Associated Tuberculosis

Anne E. Goldfeld, Children's Hospital Boston, Harvard Medical School, USA

Time is of the Essence: Lessons from the CAMELIA Trial

Keertan Dheda, University of Cape Town, South Africa
New Insights into the Pathogenesis of Drug-Resistant TB and Implications for Clinical Management

Philana Ling Lin, University of Pittsburgh, USA
Lesion Dynamics in SIV/TB Co-Infection

Short Talk(s) Chosen from Abstracts

Workshop 2: Microbiology

Short Talks Chosen from Abstracts

Pediatrics: Is Immaturity a Co-Morbidity?

Theodore H. Cohen, Yale School of Public Health, USA
TB in Children

Deborah Lewinsohn, Oregon Health & Science University, USA
Pediatric Immunity in TB

Helen McShane, Jenner Institute, UK
Vaccine Responses in Children and Adults

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 2

Impact of Co-Infections on TB Pathogenesis

Alessandro D. Sette, La Jolla Institute for Allergy & Immunology, USA
Heterologous Immunity between Mtb and NTMs

Subash S. Babu, National Institutes of Health - ICER, India
Modulation of Human Immunity to TB by Helminth Co-Infection

Padmini Salgame, Rutgers University, USA
Helminth/TB Co-Infection: Th2 Cytokines

Maziar Divangahi, McGill University, Canada
Influenza and Tuberculosis

Short Talk(s) Chosen from Abstracts

Metabolism and Co-Morbidity II

Megan Murray, Harvard Medical School, USA
Diabetes and Environmental Co-Morbidities with TB

Kanury V. S. Rao, International Centre for Genetic Engineering and Biotechnology, India
The Metabolic Interface Between Diabetes and Susceptibility to TB Infection

Hardy Kornfeld, University of Massachusetts Medical School, USA
Cellular Immunology of TB Susceptibility with Metabolic Co-Morbidity

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 3

Host-Pathogen Interactions

Priscille Marie Brodin, CIIL Institut Pasteur, France
Small Molecules of Mtb that Target the Host

Shabaana A. Khader, Children's Hospital of Pittsburgh, USA
Neutrophils in TB: The Good, the Bad and the Ugly

Jeffery S. Cox, University of California, San Francisco, USA
Targeting MTB Cytosolic Sensors

Joseph Keane, St. James's Hospital and Trinity College Dublin, Ireland
Effects of Cigarette Smoke on the Macrophage-Pathogen Interaction

Short Talk(s) Chosen from Abstracts

Workshop 3: Host-Directed Therapies

Short Talks Chosen from Abstracts

Host-Directed Therapeutics: Co-Opting Treatment of Co-Morbidities

Amit Singhal, Singapore Immunology Network, Singapore
Host-Directed Therapy for TB: The Dawn of a New Paradigm

Guy Edward Thwaites, Oxford University Clinical Research Unit, Vietnam
Aspirin, Eicosanoids and TB Meningitis

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Tuberculosis Co-Morbidities and Immunopathogenesis (B6)

February 28-March 3, 2016 • Keystone Resort • Keystone, Colorado, USA

Scientific Organizers: Hardy Kornfeld, Sarah M. Fortune and Thomas R. Hawn

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Global Health Travel Award Deadline: September 29, 2015 / Abstract & Scholarship Deadline: October 29, 2015 / Abstract Deadline: December 1, 2015 / Discounted Registration Deadline: January 5, 2016

Adrian Martineau, Queen Mary University of London, UK

Vitamin D and Phenylbutyrate as Potential Host-Directed Therapies

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 4

Departure